Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab.

The Lancet regional health. Europe·2026
Same author

European Medicines Agency approvals of new medicines in September and October 2025.

The Lancet regional health. Europe·2025
Same author

A Fast Path from Innovation to Safe and Effective Medicines.

Clinical pharmacology and therapeutics·2025
Same author

Addressing global regulatory challenges in rare disease drug development.

Drug discovery today·2025
Same author

Applying the EU Regulatory Framework to Determine the Benefit-Risk Profile of Psychedelics.

ACS pharmacology & translational science·2025
Same author

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.

Neuroscience applied·2025

相关实验视频

Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

临床表现 临床表现

Steffen Thirstrup1

  • 1European Medicines Agency, Amsterdam, Amsterdam, Netherlands.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括

全球一致的诊断标准促进了国际药物开发和监管调整. 差异需要试验复制,增加新药的成本和时间表.

科学领域:

  • 药监和药物监管 药监和药物监管
  • 临床试验设计和方法论
  • 全球卫生政策 全球卫生政策

背景情况:

  • 药品批准依赖于安全和有效使用的指导方针,根据益处:风险概况定义目标适用情况.
  • 临床试验中的患者群体决定了试验设计和进行,影响了监管机构的提交.
  • 建立明确的目标指示对于将临床证据与监管预期结合起来至关重要.

研究的目的:

  • 概述欧洲药物管理局对与诊断标准相关的药物开发挑战的立场.
  • 为解决围绕阿尔茨海默病诊断标准的持续辩论.
  • 突出诊断标准对齐对全球药物开发和监管过程的影响.

主要方法:

  • 审查当前欧洲药品署 (EMA) 的政策和指导方针.
  • 分析诊断标准对全球药物开发的影响.
  • 检查药品开发中的监管调整策略.

主要成果:

  • 全球统一的诊断标准促进国际药物开发和监管趋同.
  • 缺乏标准化的标准可能会导致重复的临床试验或旨在满足各种监管要求的试验.
  • 诊断标准的调整对于新疗法的高效和成本效益的开发至关重要.

更多相关视频

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

相关实验视频

Last Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

结论:

  • 欧洲药品管理局强调了标准化诊断标准对于有效的药物开发的重要性.
  • 协调诊断标准,特别是对于阿尔茨海默氏症等复杂疾病,对于全球监管成功至关重要.
  • 解决诊断标准方面的挑战促进了国际合作,并简化了新药的批准过程.